Bio-Imaging Technologies, Inc., a healthcare contract service organization that supports product development for the pharmaceutical, biotechnology and medical device industries, today announced it has partnered with AG Mednet, a global diagnostic imaging network, to provide a complete imaging service for clinical trials. The new service enables fast delivery of clinical trial images through a web accessible, secure network between clinical sites and Bio-Imaging’s Imaging Core Lab (ICL), increasing efficiency while reducing costs. The service, which is available immediately, has already been deployed for active studies with Bio-Imaging’s major pharmaceutical clients. “By partnering with AG Mednet, Bio-Imaging Technologies now provides our customers with many key benefits over the manual transport methods commonly used in imaging trials,” said Mark Weinstein, CEO of Bio-Imaging Technologies. “This partnership increases trial efficiency with faster delivery of the imaging data, enhances data quality with fewer site queries, and reduces cost versus today’s standard global courier shipments. As Bio-Imaging can manage all of the logistics to centralize radiologic data and provide expert independent review services for Phase I-IV clinical trials, we now provide a one-stop-shop for today’s medical researchers.” Mr. Weinstein added, “Bio-Imaging receives study related data from over 11,000 sites and 80 countries and we understand that the adoption of this new process will take time. In light of that, we will continue to support the traditional transport methods that we are currently using in over 200 ongoing clinical trials.” AG Mednet’s Clinical Trials Imaging network is a sophisticated infrastructure designed specifically for investigator sites and trial managers. At the investigator site, a web-enabled agent guides trial managers through a process to send the image studies and data directly to the ICL. The process typically takes minutes, compared to previously used methods that have taken hours or days. “AG Mednet’s extensive network is designed to route diagnostic images (both DICOM and non-DICOM based) for the most advanced studies, with sizes ranging from small CTs and MRIs to extremely large CTA/MRA and IVUS,” said Abraham Gutman, President and CEO of AG Mednet. “This partnership enables faster transmission of images to Bio-Imaging’s ICL, and the network’s advanced de-identification capabilities will expedite analysis, increase data quality, and ultimately, reduce the time it takes to conduct clinical trials.”
